SHINE Technologies and Blue Earth Therapeutics Partner for First Ilumira Supply from New Facility

SHINE Technologies, LLC (SHINE), known for its advancements in fusion-based technologies, has entered into a significant collaboration with Blue Earth Therapeutics, a subsidiary of Bracco that excels in developing state-of-the-art radiopharmaceuticals. This partnership, announced on June 6, 2024, marks a notable step in the clinical evaluation of a new treatment for prostate cancer.

SHINE has initiated this collaboration by supplying Blue Earth Therapeutics with its innovative product, Ilumira, a non-carrier added lutetium-177 (n.c.a. Lu-177) chloride. This advanced therapeutic agent is slated to play a crucial role in ongoing clinical trials aimed at finding an effective treatment for prostate cancer in men.

This development follows SHINE’s strategic submission of a Drug Master File to the U.S. Food and Drug Administration (FDA). This submission is a pivotal move, positioning SHINE on an expedited pathway to deliver high-quality solutions to its clients in the medical field.

Blue Earth Therapeutics, backed by Bracco’s extensive expertise in radiopharmaceuticals, is known for its commitment to pioneering innovative treatments. The use of Ilumira in their clinical trials underscores the potential of this substance in providing new therapeutic options for prostate cancer, a disease that continues to affect a significant number of men worldwide.

The collaboration between SHINE and Blue Earth Therapeutics is highly anticipated to accelerate the development of effective radiopharmaceutical treatments, leveraging SHINE's cutting-edge fusion technology and Blue Earth Therapeutics’ prowess in radiopharmaceutical innovation.